With the progress of society, many people’s living standards have improved, but due to work or family reasons they have ignored their own health problems, allowing some diseases to take advantage of it. Among them, colorectal cancer is a typical example. Colorectal cancer does not happen overnight. According to statistics, the time it takes a mutant cell to grow into a malignant tumor actually exceeds 30 years on average. And just inadvertently, a tiny lifestyle habit may be playing a role in carcinogenesis, and it is impossible to prevent it. In recent years, colorectal cancer has closely followed lung cancer and has become the second highest incidence cancer, which has to attract people’s attention.
Precision treatment brings new hope to colorectal cancer patients
With the deepening of research on the efficacy of targeted therapy and genotyping, targeted drugs have become a new option for individualized treatment and comprehensive treatment of patients with colorectal cancer. First-line treatment. The emergence of targeted drugs has improved the treatment expectations of patients with colorectal cancer, and its combination with chemotherapy drugs has further extended the survival time of patients.
Commonly used targeted drugs for the treatment of colorectal cancer mainly include two types of drugs that target epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), such as the former cetuximab and panib Monoclonal antibodies, the latter of which are ramucirumab, bevacizumab and regorafenib. Targeted drugs such as KRAS, BRAF, PIK3CA, MSI and PD-L1 have also entered clinical trials, and it is believed that more targeted drugs will be available in the near future to benefit patients with colorectal cancer.
Face the individual differences of colorectal cancer Gene testing is imperative
Regarding the treatment of colorectal cancer, people are more concerned about what treatment methods are currently used? The treatment of colorectal cancer is related to the tumor stage, and the treatment should follow the principle of individualized treatment. How to achieve individualized treatment? The answer is, of course, genetic testing. Only through genetic testing to understand the molecular characteristics of cancer cells can we cure the disease. As mentioned earlier, there are several targeted drugs already available, but is it enough to only detect the corresponding target of the drug? of course not.
For example, although there is no targeted drug for RAS mutations in colorectal cancer, it is also important to detect RAS genes in colorectal cancer patients. A 2008 study showed that for KRAS wild-type patients, cetuximab monotherapy can significantly prolong the OS of patients (9.5 months vs 4.8 months) compared with the best supportive treatment, but KRAS mutant patients But failed to benefit from it. This suggests that the use of cetuximab with EGFR as the target also needs to detect KRAS mutations in patients, and genetic testing has played an irreplaceable role.
Genetic testing based on second-generation sequencing can no longer meet the needs of patients
When it comes to genetic testing, the first thing that everyone thinks about is the second-generation sequencing to detect DNA mutations. Through genetic analysis, find symptomatic targeted drugs for mutation targets to guide the treatment of patients. But how many cancer patients can really benefit from second-generation sequencing? According to statistics, less than 10% of patients can detect mutation targets, and even fewer patients can continue to use targeted drugs and benefit. Most patients still rely on the treatment of chemotherapeutic drugs to prolong their survival. There are precise choices for chemotherapeutic drug selection. Instead of blindly copying the guidelines, the United States has a technology that can not only guide targeted therapy but also guide patients to chemotherapy Precise selection, through testing, can enable 95% of patients to receive treatment guidance and benefit from it.
Caris multi-platform molecular analysis is the first choice for patients
In addition to guiding targeted drugs, it can also guide the selection of chemotherapeutic drugs. This is the biggest feature of the multi-platform molecular profiling analysis of the United States Keris, and it is also the place where patients can benefit most. Kerais multi-platform molecular analysis, for all kinds of cancer patients, comprehensively analyzes the molecular biological characteristics of tumors from the DNA, RNA and protein levels, can provide more than 60 FDA-approved drug selection opportunities, and has completed 127,000 tumor map analysis , 95% of cancer patients can benefit clinically.
According to the official data of Keruisi, a large solid tumor study enrolling 1180 patients, after being guided by Keruisi multi-platform molecular analysis, prolonged survival of patients by 422 days. The average number of medications used by patients under instruction was 3.2, and the number of medications used by patients without guidance was 4.2. More medications meant that patients might need to suffer more side effects and unnecessary economic losses. What patients ca n’t imagine is that in addition to guiding the selection of targeted drugs, Keruisi can also analyze which chemotherapeutic drugs are suitable for patients. Most people know that targeted therapy is based on gene mutations to select targeted drugs Precise treatment, but in fact, the selection of chemotherapy drugs also needs guidance, and can not be copied in accordance with the treatment guidelines. Keris multi-platform molecular analysis is such a comprehensive comprehensive analysis technology, providing patients with the most accurate and suitable treatment options.
The most benefited cancers of Keruis molecular analysis are lung cancer, colorectal cancer and breast cancer. Patients can benefit from Keruis molecular analysis in the following situations, such as standard treatment of metastatic cancer with drug resistance: such as colorectal cancer, lung cancer, breast cancer, and ovarian cancer; rare cancers with few treatment options: such as sarcoma, glia Stromal tumors, metastatic carcinoma of unknown primary focus; almost no selection criteria for malignant tumors: such as melanoma, pancreatic cancer.
Colorectal cancer patients must cherish this opportunity. Through the multi-platform molecular analysis of Keruis, they can comprehensively obtain the characteristics of the cancer map. Even if there is no mutation target, Keruisi can point out which drugs can benefit clinically and which cannot benefit from chemotherapy drugs To help patients avoid unnecessary side effects.
